Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Email

Antibody Characterization Program

Illustration of scientific research elements: molecular structures, antibodies, animals (rabbit and mice), lab equipment (test tubes, petri dishes), and scientific charts. Logo in the bottom right corner reads "CPTC Characterized Antibody" with a checkmark.
Requesting Targets for Characterization

The National Cancer Institute (NCI)’s Antibody Characterization Program comprehensively characterizes monoclonal antibodies or other renewable affinity reagents for use in cancer related research via its Antibody Characterization Laboratory (ACL) located at the Frederick National Laboratory for Cancer Research (FNLCR).

The ACL not only characterizes reagent specificity and performance, but also is in alignment with the National Institutes of Health’s Rigor and Reproducibility Principles and Guidelines.

The NCI’s antibody program seeks cancer related targets from the scientific community for affinity reagent production and characterization approximately every 12 to 18 months.

Selected antibodies undergo extensive characterization, with all data on the antibody portal.

View Available Antibodies

Antibody Portal Stats

  • 968 Antibodies
  • 593 Antigen Targets

Central to reproducibility in biomedical research is being able to use well-characterized and defined reagents.

The CPTAC Antibody Portal serves as a National Cancer Institute (NCI) community resource that provides access to a large number of standardized renewable affinity reagents (to cancer-associated targets) and the accompanying characterization data for the reagents.

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Antibody Characterization Program was originally published by the National Cancer Institute.”

Email